E2D (p.Glu2Asp) variant of BCL10 (B-cell lymphoma/leukemia 10)

E2D (p.Glu2Asp) in BCL10 (B-cell lymphoma/leukemia 10) is a missense change. Clinical records from EBI and UniProt describe it as likely benign. The available variant effect predictions contribute to a CATVariant prioritization score of 0.45 / 1. The record also includes population frequency data.

E2D (p.Glu2Asp) variant details